Trial reportBrain and behavior2020
Duloxetine and pregabalin in neuropathic pain of lung cancer patients.
Trial report in Brain and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Adjusted Indirect and Mixed Comparisons of Drug Therapy for Neuropathic Cancer Pain.Pain research & management · 2026Pooled it
- Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2023Pooled it
- Duloxetine and pregabalin in neuropathic pain of lung cancer patients.Brain and behavior · 2020Trial
- Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer.BMC pharmacology & toxicology · 2026Article
- Development of a machine learning-based nomogram for predicting chronic postsurgical pain after uniportal video-assisted thoracoscopic surgery.Journal of thoracic disease · 2025Article
- Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer.JTO clinical and research reports · 2024Review
- Review
- Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists.Brain sciences · 2023Article
- Management of pain in patients with bone metastases.Frontiers in oncology · 2023Review
- High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.Drugs in context · 2023Review
- Olfactory ensheathing cells and neuropathic pain.Frontiers in cell and developmental biology · 2023Review
- New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations.Neurology international · 2021Review
- Mechanisms Underlying Gastrodin Alleviating Vincristine-Induced Peripheral Neuropathic Pain.Frontiers in pharmacology · 2021Article
- Application effects of evidence-based nursing in pain nursing of advanced lung cancer.American journal of translational research · 2021Article
- Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeuropathic pain occurs in 1% of the population and is difficult to manage. This chronic pain causes psychological distress and impacts patient's quality of life, especially in cancer patients. The aim of this study was to show and compare the efficacy of pregabalin and duloxetine, which are reported in the group of first-line treatment at European Federation of Neurological Societies (EFNS) guidelines on the pharmacological treatment of neuropathic pain (2010 revision) in lung cancer patients by using visual analogue scale (VAS) and Leeds Assessment of Neuropathic Symptoms and Sign (LANSS). PATIENTS AND
methodsA prospective, randomized, open label, 3 month of study was conducted. A total of 44 patients that were diagnosed with neuropathic pain (14 women and 30 men) were included in the study. Patient's LANSS and VAS values were recorded before treatment. Then, 22 patients undergo pregabalin and 22 patients undergo duloxetine therapy. But due to side effects (dizziness, constipation), two patients had stopped to use pregabalin. Their LANSS and VAS values were recorded after 1 and 3 months of therapy.
resultsWhen we compare LANSS and VAS scores before treatment, after 1 and 3 months of treatment with pregabalin and duloxetine, a significant decrease was observed in both groups at the 1 and 3 months (p < .01). Duloxetine is superior to pregabalin in reducing the LANSS scores when we compare two groups.
conclusionsBoth duloxetine and pregabalin are effective in the treatment of neuropathic pain of lung cancer patients. And as far as we know, this is the first study comparing the efficacy of duloxetine and pregabalin in the neuropathic pain of lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.